- Home
- TEI vs GALT Comparison
TEI vs GALT Comparison
Compare TEI & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TEI | GALT |
|---|---|---|
| Founded | 1993 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 310.3M | 297.0M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | TEI | GALT |
|---|---|---|
| Price | $6.64 | $4.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 137.5K | ★ 326.7K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 10.51% | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.75 | $2.03 |
| 52 Week High | $7.00 | $7.13 |
Technical Indicators
Market Signals| Indicator | TEI | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 42.39 | 64.43 |
| Support Level | $6.24 | $2.74 |
| Resistance Level | $6.68 | $4.35 |
| Average True Range (ATR) | 0.08 | 0.31 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 0.00 | 91.47 |
Price Performance
Historical ComparisonAbout TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.